Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | NPC1 | O15118 | 2/20 | 0.59 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | ATF4 | P18848 | 1/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.40 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30026239 | 0.86 | MCL1 (0.61) | MAPTNPC1MAPK1HSD17B10MCL1 | |
| SCHEMBL1576408 | 0.86 | MCL1 (0.61) | MAPTNPC1MAPK1HSD17B10MCL1 | |
| SCHEMBL21436881 | 0.86 | ATF4 (0.53) | MAPTNPC1MAPK1HSD17B10MCL1 | |
| SCHEMBL14683466 | 0.85 | MAPT (0.58) | MAPTNPC1MAPK1HSD17B10MCL1 | |
| SCHEMBL11948007 | 0.85 | MAPT (0.58) | MAPTNPC1MAPK1HSD17B10MCL1 | |
| SCHEMBL29689485 | 0.84 | MCL1 (0.53) | NPC1MCL1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL7413146 | 0.84 | MCL1 (0.53) | NPC1MCL1RAB9ASMN1; SMN2MEN1 | |
| SCHEMBL1256959 | 0.82 | NPC1 (0.56) | MAPTNPC1MAPK1HSD17B10 | |
| SCHEMBL12468989 | 0.82 | MAPT (0.56) | MAPTNPC1MAPK1HSD17B10MCL1 | |
| SCHEMBL30342219 | 0.82 | MAPT (0.63) | MAPTNPC1MAPK1HSD17B10HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112218851-A | Modulators of integrated stress pathways | 卡里科生命科学有限责任公司 | 2021-01-12 | — | — | CN | disclosed |
| US-20200347033-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | CALICO LIFE SCIENCES LLC | 2020-11-05 | — | — | US | disclosed |
| EP-3704091-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | Calico Life Sciences LLC (US) | 2020-09-09 | — | — | EP | disclosed |
| EP-3212647-B1 | NOVEL PYRIDOPYRIMIDINONE COMPOUNDS FOR MODULATING THE CATALYTIC ACTIVITY OF HISTONE LYSINE DEMETHYLASES (KDMS) | DONG A ST CO LTD (KR) | 2019-04-03 | — | — | EP | disclosed |
| US-9834550-B2 | Pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (KDMs) | DONG-A ST CO., LTD. (KR) | 2017-12-05 | — | — | US | disclosed |
| US-9834550-B2 | Pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (KDMs) | DONG-A ST CO., LTD. (KR) | 2017-12-05 | — | — | US | disclosed |
| US-9834550-B2 | Pyridopyrimidinone compounds for modulating the catalytic activity of histone lysine demethylases (KDMs) | DONG-A ST CO., LTD. (KR) | 2017-12-05 | — | — | US | disclosed |
| EP-3212647-A2 | NOVEL PYRIDOPYRIMIDINONE COMPOUNDS FOR MODULATING THE CATALYTIC ACTIVITY OF HISTONE LYSINE DEMETHYLASES (KDMS) | Dong-A ST Co., Ltd. (KR) | 2017-09-06 | — | — | EP | disclosed |
| WO-2016068580-A2 | NOVEL PYRIDOPYRIMIDINONE COMPOUNDS FOR MODULATING THE CATALYTIC ACTIVITY OF HISTONE LYSINE DEMETHYLASES (KDMS) | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2016-05-06 | — | — | WO | disclosed |
| WO-2016068580-A2 | NOVEL PYRIDOPYRIMIDINONE COMPOUNDS FOR MODULATING THE CATALYTIC ACTIVITY OF HISTONE LYSINE DEMETHYLASES (KDMS) | DONG-A SOCIO HOLDINGS CO., LTD. (KR) | 2016-05-06 | — | — | WO | disclosed |
| US-20160122343-A1 | Novel Pyridopyrimidinone Compounds for Modulating the Catalytic Activity of Histone Lysine Demethylases (KDMs) | DONG-A ST CO., LTD. (KR) | 2016-05-05 | — | — | US | disclosed |
| US-20160122343-A1 | Novel Pyridopyrimidinone Compounds for Modulating the Catalytic Activity of Histone Lysine Demethylases (KDMs) | DONG-A ST CO., LTD. (KR) | 2016-05-05 | — | — | US | disclosed |
| US-8362032-B2 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2013-01-29 | — | — | US | disclosed |
| EP-1891063-B1 | BICYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2012-07-25 | — | — | EP | disclosed |
| US-20110059965-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2011-03-10 | — | — | US | disclosed |
| US-7786137-B2 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-08-31 | — | — | US | disclosed |
| US-20090012117-A1 | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMACEUTICALS INCORPORATED | 2009-01-08 | — | — | US | disclosed |
| CN-101218235-A | Bicyclic derivatives as modulators of ion channels | VERTEX PHARMA (US) | 2008-07-09 | — | — | CN | disclosed |
| EP-1891063-A2 | BICYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | Vertex Pharmaceuticals, Inc. (US) | 2008-02-27 | — | — | EP | disclosed |
| WO-2006122014-A2 | BICYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2006-11-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090012117-A1 | Bicyclic derivatives as modulators of ion channels | CACNA1C, CACNA1B, CACNA1D | MAPT 2309/4885NPC1 1028/4885MAPK1 3665/4885 |
| US-20110059965-A1 | BICYCLIC DERIVATIVES AS MODULATORS OF ION CHANNELS | CACNA1C, CACNA1B, CACNA1D | MAPT 2309/4885NPC1 1028/4885MAPK1 3665/4885 |
| US-20160122343-A1 | Novel Pyridopyrimidinone Compounds for Modulating the Catalytic Activity of Histone Lysine Demethylases (KDMs) | KDM1B, KDM1A, KDM3B | MAPT 3081/4885NPC1 4377/4885MAPK1 982/4885 |
| US-20200347033-A1 | MODULATORS OF THE INTEGRATED STRESS PATHWAY | ATF4, ATF1, IRF3 | MAPT 3796/4885NPC1 1252/4885MAPK1 160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.